



pharmaceuticals

Neuren Pharmaceuticals Ltd
Level 3, 2-6 Park Avenue, Grafton
P O Box 9923
Newmarket
Auckland 1030
New Zealand
Telephone: +64 9 367 7167
Facsimile: +64 9 367 7186
enquiry@neurenpharma.com
www.neurenpharma.com

7 February 2005

Former Pfizer Executive Dr Graeme Howie to Join Neuren Board

7th February 2005 – Former Pfizer/Pharmacia Senior Executive Dr Graeme Howie has joined the Board of Neuren Pharmaceuticals Limited as an Australian resident Non-Executive Director.

Dr Howie has over 27 years of management experience in the international pharmaceutical industry with a strong and diverse background in R&D, product development, manufacturing and commercial fields. His most recent experience is in recombinant biotech product development. He was, until December 2004 a senior executive at Pfizer, based in New York. His most recent role was leading the team developing the world's best selling recombinant human growth hormone (Genotropin) and related compounds and was responsible for all development activities including clinical trials and registration activities. Genotropin has annual sales of approximately USD\$760 million.

Dr Howie has extensive international experience in technical and commercial due diligence activities, including in-licensing. Dr Howie also led and was responsible for new delivery route feasibility studies on human growth hormone and has been responsible for the development and registration of various products throughout USA, Europe, Australia and the Asian export markets. Dr Howie retired from Pfizer in December 2004 to return to Australia.

“Dr Howie brings a wealth of critical industry experience to Neuren and his proven ability will be of great benefit to our Company, particularly in drug development and commercialisation. He has an extensive network of contacts throughout the international pharmaceutical industry. By joining the Board he expands our capacity to successfully develop drugs and position them for partnering and licensing. His “big Pharma” experience will be invaluable.” David Clarke, CEO of Neuren said today.

Neuren Pharmaceuticals is a biotechnology company developing novel therapeutics in the fields of neuroprotection and metabolic disorders. Neuren holds 72 patents across five product families and has an experienced international team of scientists and managers with strong capability in biotechnology. Neuren's IP targets markets with large unmet needs and limited competition. Neuren enjoys strong commercial and development partnerships with Pfizer Inc., Duke University and the US Army's Walter Reed Hospital among others.

For more information please contact:

David Clarke, CEO Neuren Pharmaceuticals Ltd.,
Tel +64 (0)21 988052

Rod Nockles Financial & Corporate Relations

Tel: +61 3 9629 3000, Fax: +61 3 9629 3300, Mobile: + 61 (0) 419 691 323, Email: r.nockles@fcr.com.au